AI-generated from publicly available materials.Evaxion has been awarded the prestigious International Prix Galien Award for its innovative AI-Immunology™ platform, recognized as the best digital health solution.
This accolade, presented at the American Museum of Natural History in New York City, underscores the significance of AI-Immunology™, which employs artificial intelligence to decode the human immune system, paving the way for novel immunotherapies targeting cancer, autoimmune, and infectious diseases. The platform has already demonstrated its potential, particularly with the personalized cancer vaccine EVX-01, which has shown promising results in clinical trials for advanced melanoma.
The Prix Galien, often dubbed the Nobel Prize of biopharmaceutical research, is awarded biennially to nominees who have previously received a national Prix Galien award. Evaxion's recognition follows its earlier accolades, including the Prix Galien UK Award for Best Digital Health Solution and the Best Medical Technology/AI Advances award in the Nordic region. This consistent recognition highlights the company’s commitment to advancing medical innovation through AI.
Evaxion's CEO, Helen Tayton-Martin, expressed pride in the acknowledgment of their work, emphasizing the platform's two-decade evolution into a leading tool for immune drug target discovery. As the demand for personalized medicine grows, Evaxion's AI-driven approach positions it at the forefront of transforming cancer treatment and addressing significant unmet medical needs in the healthcare landscape.